Table 2 Patients with PDGFRA point... | American Society of Hematology

Table 2

Patients with PDGFRA point mutations

ID	Clinical diagnosis	Mutation	Polymorphism	PDGFRA overexpression	Sex	Age, y	Eosinophil count, /μL
1	HES	R481G	P567P	Yes	Male	76	276*
2	HES	I562M, H570R	S478P, A603A	Yes	Male	76	810*
3	HES and CLL	H650Q, R748G	P567P	Yes	Female	65	4320
4	HES	L705P	P567P	Yes	Male	70	5334
5	HES	Y849S	P567P, V824V	No	Male	67	NA
6	HES	Y849S, L507P	None	No	Male	25	NA
7	HES	N659S	P567P	No	Female	45	204*

ID	Clinical diagnosis	Mutation	Polymorphism	PDGFRA overexpression	Sex	Age, y	Eosinophil count, /μL
1	HES	R481G	P567P	Yes	Male	76	276*
2	HES	I562M, H570R	S478P, A603A	Yes	Male	76	810*
3	HES and CLL	H650Q, R748G	P567P	Yes	Female	65	4320
4	HES	L705P	P567P	Yes	Male	70	5334
5	HES	Y849S	P567P, V824V	No	Male	67	NA
6	HES	Y849S, L507P	None	No	Male	25	NA
7	HES	N659S	P567P	No	Female	45	204*

HES indicates idiopathic hypereosinophilic syndrome; CLL, chronic lymphocytic leukemia; and NA, not available.

During treatment with prednisone and cyclophosphamide.